Lupin (company)
Tracked across 5 events · 50 articles · First seen Mar 20, 2025 · Last active Jul 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Lupin (company) entered a licensing and supply agreement with Astec LifeSciences to co-market Semaglutide Injection in India, gaining semi-exclusive rights to distribute the drug under its own brand names. This enhances its diabetes portfolio and strengthens its commitment to advanced cardio-metabolic treatments.
Mar 17, 2026 · 7 articles
Business
Impact: Lupin (company) completed the acquisition of VISUfarma, significantly expanding its ophthalmology portfolio and strengthening its presence in Europe. This acquisition is expected to be immediately accretive and accelerate its specialty franchise build-out.
Apr 02, 2026 · 13 articles
Regulatory
Impact: Lupin (company) received tentative approval from the U.S. FDA for its Enzalutamide Tablets, which is a positive development for the company as it expands its product offerings and market reach.
Jun 26, 2026 · 16 articles
Business
Impact: Lupin (company) was recognized as one of the World's Most Sustainable Companies by TIME and Statista, highlighting its strong ESG performance and commitment to sustainability.
Jul 06, 2026 · 6 articles
Business
Impact: Lupin (company) is preparing to roll out generic semaglutide and has formed a licensing partnership with Astec LifeSciences, aiming to compete in the Indian weight-loss drug market.
Mar 20, 2026 · 8 articles
100
Lupin (company) debuted on listLupin on World's...
100
United States — Food and Drug Administration granted tentative approval Lupin (company)Lupin gets US FDA approval
ERGEN INTELLIGENCE
Track Lupin (company) live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard